{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:53:02Z","timestamp":1791553982987,"version":"4.3.4"},"reference-count":10,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"abstract":"<jats:p>Approvals of new therapeutics are increasingly restricted to specified biomarker subgroups, even where pivotal clinical studies meet primary endpoints in broader \u201call\u2010comers\u201d populations. In this article, we discuss the potential factors that increase the likelihood of approvals in biomarker subpopulations rather than all\u2010comers. We outline mitigation strategies drug developers can pursue to plan for potential label restrictions and achieve companion diagnostic readiness, ensuring patients receive timely access to innovative medicines.<\/jats:p>","DOI":"10.1002\/cpt.70521","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:32:02Z","timestamp":1791552722000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Future of all\u2010Comers Trials in the Era of Precision Oncology"],"prefix":"10.1002","author":[{"given":"J. Andrew","family":"Williams","sequence":"first","affiliation":[{"name":"Precision Diagnostics Development AstraZeneca R&amp;D  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Global Business Services (R&amp;D), AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"MacNish Porter","sequence":"additional","affiliation":[{"name":"Precision Diagnostics Development AstraZeneca R&amp;D  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Cui","sequence":"additional","affiliation":[{"name":"Precision Diagnostics Development AstraZeneca R&amp;D  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten S.","family":"Gutjahr","sequence":"additional","affiliation":[{"name":"Precision Diagnostics Development AstraZeneca R&amp;D  Cambridge UK"},{"name":"Precision Diagnostics Development AstraZeneca R&amp;D  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"e_1_2_5_1_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_2_5_2_1","unstructured":"Society of Gynecologic Oncology.Summary:Revisions to FDA Approvals for PARP Inhibitors in the Management of Ovarian Cancer<https:\/\/www.sgo.org\/resources\/revisions\u2010to\u2010fda\u2010approvals\u2010for\u2010parp\u2010inhibitors\/>. Accessed December 2025."},{"key":"e_1_2_5_3_1","unstructured":"FDA.Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting September 26 2024(2025) <https:\/\/www.fda.gov\/media\/184929\/download>. Accessed 27 November 2025."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187"},{"key":"e_1_2_5_6_1","unstructured":"Sanofi.Sanofi and Regeneron provide regulatory update on Libtayo\u00ae (cemiplimab\u2010rwlc) in advanced cervical cancer(2022) <https:\/\/www.sanofi.com\/en\/media\u2010room\/press\u2010releases\/2022\/2022\u201001\u201028\u201012\u201000\u201000\u20102374983>. Accessed December 2025."},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.03.008"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01977-y"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70521","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:32:04Z","timestamp":1791552724000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":10,"alternative-id":["10.1002\/cpt.70521"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70521","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cpt.70521"}}